Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study of the Safety and Efficacy of LY2623091 in Chronic Kidney Disease Patients
2012-000773-23Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of LY-2623091 in chronic kidney disease (CKD), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline to 21 days in proteinuria based on 24-hour pooled urine. Started Mar 2012; status: terminated.
02
Drugs
LY-2623091
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2012-000773-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000773-23.